Search results for: Multi-Indication Medicines
Filter search results
OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes
26 October 2016
…indications and decide whether they are eligible for inclusion in the CDF, which will become a ‘managed access fund’. This research estimates the number of current CDF indications that may…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
…clinical trials for dementia indications. Of these, 110 had been terminated early, only 45% of which had a reported reason for this early termination. Of the 45% which did provide…
The Expanding Value Footprint of Oncology Treatments
1 May 2014
…for eight years or more are likely to have been approved for additional indications. New indications, for example, may be for use in a different cancer, disease stage, treatment stage,…
OHE Study Projecting UK Medicines Expenditure Extended to 2018
18 November 2013
The extended analysis is outlined in the slide presentation in this post. PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015. The PPRS 2014 Heads of…
Medicines and the Quality of Life
1 September 1982
…problem of evaluating the contribution of medicines to the quality of life. It… Previous studies concerned with the benefits of modern medicines have concentrated mainly on their economic consequences (Wells…
Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
1 August 2018
This OHE Consulting Report reviews “Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS.” The project was funded by the ABPI. For the year 2015/16, the Treasury reported…
OHE Posters at HTAi: Tokyo 2016
24 May 2016
…and Karla Hernandez-Villafuerte at the meeting can be found in a previous blog post. Multi-Indication Pricing: Pros, Cons and Applicability by Jorge Mestre-Ferrandiz Multi-indication pricing (MIP) involves setting a different price…
Around The World in HTAs: Italy – What’s Next?
20 April 2023
…price negotiation, reimbursement, and entry agreement negotiations) are mostly managed by the Regions. Assessment of medicines The assessment of new medicines is managed by the HTA & Pharmaceutical Economics Department…
Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
5 June 2025
…Innovate UK, with OHE among the collaborators. Share this: Do Medicines Always Work as Intended? An estimated 70% of the UK population have received prescription medication. However, a substantial proportion of these medicines…